This trial is testing whether thyroid hormone therapy can help people with heart failure and low T3 levels.
- Heart Failure with Reduced Ejection Fraction
2 Primary · 4 Secondary · Reporting Duration: continuous during intervention (14 days)
2 Treatment Groups
1 of 2
1 of 2
28 Total Participants · 2 Treatment Groups
Primary Treatment: Liothyronine (LT3) · Has Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What aims is this research endeavor striving to fulfill?
"This 14-day clinical trial has one primary aim: achieving T3 Level. Secondary objectives include measuring NT-proBNP, Quality of Life through the KCCQ scale, and VO2 Max peak rate of oxygen consumption during exercise." - Anonymous Online Contributor
How many participants is this research endeavor accommodating?
"Affirmative. According to information published on clinicaltrials.gov, this medical study is still seeking patients to enroll in their trial. The initial posting date was February 11th 2020 and the listing has been updated most recently on August 2nd 2022; the investigators are looking for 28 individuals across a single site." - Anonymous Online Contributor
Are there any open enrollments for this medical experiment currently?
"This medical study, which was first shared on 2nd November 2020 is presently enrolling participants. Clinicaltrials.gov's records confirm that the trial has been updated as recently as 8th August 2022." - Anonymous Online Contributor